A Phase 1/2 interventional study of INV-102 and Vehicle in Dry Eye Disease, sponsored by Invirsa, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Invirsa, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 203rd largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2022, is one of 17 in phase 1/2, and was the 420th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
Invirsa, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Invirsa, Inc. has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.
Key Inclusion Criteria:
Key Exclusion Criteria:
Part 1, Cohort 1: INV-102 ophthalmic solution 0.1% administered twice daily for 2 weeks
Drug: INV-102
Part 1, Cohort 2: INV-102 ophthalmic solution 0.25% administered twice daily for 2 weeks
Drug: INV-102
Part 1, Cohort 3: INV-102 ophthalmic solution 0.7% administered twice daily for 2 weeks
Drug: INV-102
Part 1, Cohort 4: INV-102 ophthalmic solution 0.7% administered three times daily for 2 weeks
Drug: INV-102
Part 2, Cohort 5: INV-102 ophthalmic solution administered for 2 weeks using a dose based on the results from Part 1, Cohorts 1 to 4
Drug: INV-102
Part 1 (Cohorts 1-4) and Part 2 (Cohort 5): Vehicle ophthalmic solution administered two or three times daily (dependent on the cohort and the frequency of dosing of INV-102) for 2 weeks
Drug: Vehicle
INV-102 Ophthalmic Solution
Vehicle Ophthalmic Solution
Part 1: Number of Subjects With At Least One (1) Treatment-Emergent Adverse Event
The primary endpoint in Part 1 of this First-in-Human (FIH) study was treatment-emergent adverse events (TEAEs) assessed across multiple dosing concentrations and dosing regimens.
Time frame: From first dose through study completion (Day 22)
Part 2: Change From Baseline to Day 15 in the Eye Dryness Score From the Dry Eye Disease (DED) Symptom Visual Analog Scale (VAS)
The primary endpoint in Part 2 of the study was change from Baseline to Day 15 in the Eye Dryness Score in the study eye from the DED symptom VAS. The dry eye disease symptom visual analog scale consisted of various DED symptom parameters and was completed by subjects for each eye individually. Subjects were asked to rate their discomfort from 0 (no discomfort) to 100 (maximal discomfort) for each of the DED symptoms by placing a single vertical mark on a horizontal line based on the extent of their symptoms.
Time frame: Day 15
Part 2: Change From Baseline to Day 15 in the Eye Dryness Composite Score
The secondary endpoint in Part 2 of the study was change from Baseline to Day 15 in the Eye Dryness Composite Score in the study eye. The eye dryness composite score (points) combines the change from Baseline in eye dryness score from the DED symptom VAS and the change from Baseline in corneal fluorescein staining score. VAS eye dryness scores were rated by subjects on a scale of 0 (no discomfort) to 100 (maximal discomfort). Corneal fluorescein staining assessments were performed using the National Eye Institute/Industry grading scale to score each of 5 corneal zones on a 0 (no ocular surface disease) to 3 (severe ocular surface disease) scale (with a total score of 0 to 15). The calculated eye dryness composite score can range from -100 points to 100 points (positive values indicate worsening of dry eye disease signs and symptoms; negative values indicate improvement).
Time frame: Day 15
| Milestone | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 12 | 32 | 16 |
| Completed | 6 | 6 | 6 | 6 | 12 | 32 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The primary endpoint in Part 1 of this First-in-Human (FIH) study was treatment-emergent adverse events (TEAEs) assessed across multiple dosing concentrations and dosing regimens.
| Participants | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle |
|---|---|---|---|---|---|
| Part 1: Number of Subjects With At Least One (1) Treatment-Emergent Adverse Event | 2 | 1 | 0 | 2 | 1 |
The primary endpoint in Part 2 of the study was change from Baseline to Day 15 in the Eye Dryness Score in the study eye from the DED symptom VAS. The dry eye disease symptom visual analog scale consisted of various DED symptom parameters and was completed by subjects for each eye individually. Subjects were asked to rate their discomfort from 0 (no discomfort) to 100 (maximal discomfort) for each of the DED symptoms by placing a single vertical mark on a horizontal line based on the extent of their symptoms.
| score on a scale | Part 2 0.7% INV-102 BID | Part 2 Vehicle |
|---|---|---|
| Part 2: Change From Baseline to Day 15 in the Eye Dryness Score From the Dry Eye Disease (DED) Symptom Visual Analog Scale (VAS) | -15.50 ± 28.488 | -21.20 ± 22.056 |
The secondary endpoint in Part 2 of the study was change from Baseline to Day 15 in the Eye Dryness Composite Score in the study eye. The eye dryness composite score (points) combines the change from Baseline in eye dryness score from the DED symptom VAS and the change from Baseline in corneal fluorescein staining score. VAS eye dryness scores were rated by subjects on a scale of 0 (no discomfort) to 100 (maximal discomfort). Corneal fluorescein staining assessments were performed using the National Eye Institute/Industry grading scale to score each of 5 corneal zones on a 0 (no ocular surface disease) to 3 (severe ocular surface disease) scale (with a total score of 0 to 15). The calculated eye dryness composite score can range from -100 points to 100 points (positive values indicate worsening of dry eye disease signs and symptoms; negative values indicate improvement).
| points | Part 2 0.7% INV-102 BID | Part 2 Vehicle |
|---|---|---|
| Part 2: Change From Baseline to Day 15 in the Eye Dryness Composite Score | -10.458 ± 15.876 | -13.267 ± 13.833 |
Collected over From first dose through study completion (Day 22). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 0.1% INV-102 BID | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 0.25% INV-102 BID | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 0.7% INV-102 BID | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1 0.7% INV-102 TID | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 Vehicle | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Part 2 0.7% INV-102 BID | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Part 2 Vehicle | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Event | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle |
|---|---|---|---|---|---|---|---|
| Eye painEye disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/32 | 0/16 |
| Vision blurredEye disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/32 | 0/16 |
| PneumoniaInfections and infestations | 0/6 | 1/6 | 0/6 | 0/6 | 0/12 | 0/32 | 0/16 |
| Conjunctival stainingInvestigations | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/32 | 0/16 |
| DysgeusiaNervous system disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/32 | 0/16 |
| Vital dye staining cornea presentInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 1/12 | 0/32 | 0/16 |
| BlepharitisEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/32 | 1/16 |
| Dry eyeEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/32 | 1/16 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/32 | 1/16 |
| Age, Continuous(years) | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.8 ± 6.52 | 67.8 ± 9.62 | 61.3 ± 12.53 | 55.8 ± 14.62 | 67.4 ± 13.87 | 60.2 ± 11.91 | 65.0 ± 11.68 | 62.4 ± 12.11 |
| Sex: Female, Male(Participants) | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 5 | 4 | 3 | 5 | 8 | 19 | 10 | 54 |
| Male | 1 | 2 | 3 | 1 | 4 | 13 | 6 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 6 | 6 | 6 | 6 | 12 | 31 | 15 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 2 | 1 | 0 | 1 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 1 | 2 | 3 | 9 | 1 | 20 |
| White | 4 | 4 | 3 | 3 | 9 | 21 | 13 | 57 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1 0.1% INV-102 BID | Part 1 0.25% INV-102 BID | Part 1 0.7% INV-102 BID | Part 1 0.7% INV-102 TID | Part 1 Vehicle | Part 2 0.7% INV-102 BID | Part 2 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 12 | 32 | 16 | 84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in May 2023, 8 months.
Results were first posted in Apr 2026, 2 years 11 months after primary completion. A results delay was requested in Apr 2024.
Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: INV-102
Invirsa, Inc.